News | Peripheral Artery Disease (PAD) | October 19, 2015

VIVA Physicians Announce Late-Breaking Clinical Trials for VIVA 15 Conference

Annual meeting for vascular medicine and intervention will include presentations on new devices and procedures, plus economic and clinical impacts

VIVA 15 conference, late-breaking clinical trials, VIVA Physicians

October 19, 2015 — Vascular Interventional Advances (VIVA) Physicians, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through education and research, announced the late-breaking sessions at its annual conference, VIVA 2015. Sixteen trial results, featuring the latest in vascular technology and devices, will be released for the first time Nov. 2-3 at the Wynn Las Vegas.

Presentations of the late-breaking trials (including the embargoed results) will be presented during the General Session and highlighted during press conferences.

Scheduled presentations cover numerous categories, including:

New Devices

  • Autogenous Arteriovenous Fistula Creation for Hemodialysis Access: Preliminary Results of the NEAT Trial
  • First-in-Man Study of the MobiusHD for the Treatment of Resistant Hypertension
  • Results of the VISION (combined imaging/atherectomy) Trial

New Procedures

  • Percutaneous Endovascular Bypass of Long SFA Occlusions: Interim Trial Results

Drug-eluting Stents and Drug Coated Balloons

  • MAJESTIC: DES 12-Month Performance Overall and in Diabetic Patients
  • Results from the IN.PACT Global Study
  • Results from the IN.PACT SFA IDE Trial
  • ILLUMENATE FIH: Two-year Results on the Stellarex DCB without Pre-dilatation
  • The Lutonix Global DCB Registry in Complex Femoro-popliteal Lesions
  • Zilver PTX Post-Market Surveillance Study in Japan: 24 Month Results

Aortic Aneurysm Repair

  • Least Invasive Fast-track EVAR: Midterm Results of the Multicenter LIFE registry
  • Endovascular Repair in Acute Type B Aortic Dissection: Two-year Results from the Valiant US-IDE Study
  • Four-Year Results Evaluating the Safety and Effectiveness of the Ovation System

Economic & Clinical Impact

  • DURABILITY Iliac & VISIBILITY Iliac Combined Clinical Trials
  • The SAPPHIRE Worldwide Study, the largest CAS experience ever presented
  • Economic Analysis of Endovascular Interventions to Treat Femoro-popliteal Artery Disease

For more information:

Related Content

ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study| June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study| August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init